Low molecular weight fragment of heparin, q.v., prepd by alkaline depolymerization of a benzylic ester of porcine intestinal mucosal heparin. The majority of components present a 2-O-sulfo-α-l-threo-hex-4-enopyranuronic acid structure at the non-reducing end and a 2-N,6-O-disulfo-d-glucosamine structure at the reducing end of the chain. Average mol wt ≈4500 daltons. Prepn: J. Mardiguian, EP 40144 (1981 to Pharmindustrie), C.A. 96, 218191s (1982). Determn in human plasma: L. Bara et al., Haemostasis 17, 127 (1987). Symposium on pharmacology and clinical efficacy: ibid. 16, 69-188 (1986). Review of development and clinical experience: J. M. Galla, K. W. Mahaffey, Expert Opin. Pharmacother. 6, 1241-1251 (2004); of pharmacology and use in prevention and treatment of deep venous thrombosis: M. M. Buckley, E. M. Sorkin, Drugs 44, 465-497 (1992); in unstable angina: S. Noble, C. M. Spencer, ibid. 56, 259-272 (1998); in acute coronary syndromes: S. Lee, C. M. Gibson, Expert Rev. Cardiovasc. Ther. 5, 387-399 (2007).
Antithrombotic.
Antithrombotic